10-Q: 10x Genomics Reports First Quarter 2024 Results with Revenue Growth Driven by Spatial Instruments

10x Genomics saw a 5% increase in revenue year-over-year in Q1 2024, driven by strong growth in spatial instrument sales, though consumables revenue declined slightly.

Summary

• 10x Genomics reported a revenue of $141 million for the first quarter of 2024, a 5% increase compared to $134.3 million in the same period of 2023.
• The company experienced a significant increase in spatial instrument revenue, which rose by 133% to $17.6 million, while chromium instrument revenue decreased by 32% to $7.9 million.
• Consumables revenue saw a slight decrease of 2%, totaling $110.3 million, with chromium consumables declining and spatial consumables increasing.
• The company's gross profit was $92.9 million, with a gross margin of 66%, down from 73% in the first quarter of 2023, due to product mix and royalty obligations.
• Operating expenses totaled $154.4 million, with research and development expenses at $68.6 million and selling, general, and administrative expenses at $85.8 million.
• The company reported a net loss of $59.9 million, or $0.50 per share, compared to a net loss of $50.7 million, or $0.44 per share, in the first quarter of 2023.
• 10x Genomics had $371.8 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
• The company anticipates capital expenditures between $15 million and $20 million over the next 12 months.

Sentiment

Score: 5

Explanation: The document presents mixed results. While there is strong growth in spatial instruments, the overall financial performance is worse than the previous year with increased losses and decreased gross margin. The ongoing legal battles and future uncertainties temper the positive aspects.

Positives

• Spatial instrument revenue saw a significant increase of 133%, demonstrating strong market interest in the company's new spatial analysis products.
• Service revenue increased by 91%, indicating growth in post-warranty service contracts.
• The company maintains a strong cash position with $371.8 million in cash, cash equivalents, and marketable securities.
• Interest income increased by $0.9 million due to higher interest rates on cash and marketable securities.

Negatives

• The company experienced a net loss of $59.9 million, an increase from the $50.7 million loss in the same quarter last year.
• Gross margin decreased by 7 percentage points to 66%, primarily due to product mix and royalty obligations.
• Chromium instrument revenue decreased by 32%, indicating a potential slowdown in demand for these products.
• Consumables revenue decreased slightly by 2%, driven by lower chromium consumables sales.
• Operating expenses increased to $154.4 million, driven by higher legal costs and facilities expenses.

Risks

• The company is involved in multiple ongoing legal proceedings, including intellectual property disputes, which could result in significant costs and impact the business.
• The company's gross margin is expected to trend lower due to product mix and royalty obligations.
• The company has incurred net losses since inception and expects to continue to incur operating losses in the near term.
• The company's future capital requirements will depend on various factors, including revenue growth, research and development efforts, and potential acquisitions.
• The company's cash and cash equivalents are held in accounts with major financial institutions, which are subject to market conditions and could be impacted by institutional failures.

Future Outlook

The company expects to continue to incur operating losses in the near term and anticipates capital expenditures between $15 million and $20 million over the next 12 months. They also expect operating expenditures to increase in 2024 and beyond as they invest in research and development, commercial efforts, and talent retention.

Management Comments

• Management believes that potential increases for average selling price, as well as potential opportunities for cost reductions due to economies of scale, will improve instrument margin over the long term.
• Management takes a long-term view in growing and scaling the business and regularly reviews acquisition and investment opportunities.

Industry Context

The life sciences technology industry is highly competitive, with companies constantly innovating and developing new products. 10x Genomics' focus on spatial biology and single-cell analysis positions it in a growing market segment. The company's legal battles highlight the importance of intellectual property in this sector.

Comparison to Industry Standards

• While specific competitor results are not detailed in this document, 10x Genomics' revenue growth of 5% is moderate compared to some high-growth biotech companies, but the 133% growth in spatial instruments is a positive sign.
• The decrease in gross margin to 66% is a concern, as many established life science companies aim for higher margins, often above 70%.
• The ongoing legal battles are not unique to 10x Genomics, as intellectual property disputes are common in the biotech industry, with companies like Illumina and Pacific Biosciences also facing similar challenges.
• The company's cash position of $371.8 million is relatively strong, providing a buffer for continued operations and investments, but the ongoing losses will need to be addressed to ensure long-term sustainability.

Legal Proceedings

• The company is involved in multiple ongoing legal proceedings, including intellectual property disputes with NanoString, Vizgen, Parse, and Curio.
• A jury found that NanoString willfully infringed the asserted patents and awarded the company more than $31 million in damages, but collection is uncertain due to NanoString's bankruptcy filing.
• The company has filed suits against Vizgen, Parse, and Curio for patent infringement.
• Vizgen has filed counterclaims against the company alleging patent infringement and tortious interference.
• Parse has filed petitions for inter partes review (IPR) of the patents asserted by the company.
• The company has filed a request for a preliminary injunction against Curio in the Unified Patent Court (UPC) which was granted.

Stakeholder Impact

• Shareholders are impacted by the increased net loss and decreased gross margin.
• Employees are impacted by the company's ongoing investments in research and development and commercial efforts.
• Customers are impacted by the company's new product offerings and ongoing legal proceedings.
• Suppliers are impacted by the company's manufacturing costs and supply chain.
• Creditors are impacted by the company's financial performance and cash position.

Next Steps

• The company will continue to invest in research and development.
• The company will continue to pursue commercial efforts to support revenue growth.
• The company will continue to defend its intellectual property portfolio.
• The company will continue to evaluate market conditions and may pursue additional sources of funding.

Key Dates

Keywords

Genomics, Spatial Instruments, Chromium Instruments, Consumables, Life Sciences, Biotechnology, Single Cell Analysis, Revenue, Gross Margin, Net Loss, Intellectual Property, Legal Proceedings